Background/Objectives: Several gene targets were identified for psoriasis. Some are currently being explored as potential therapeutic targets, including CCL11. Our task was to prove a possible association of single-nucleotide polymorphisms +67 G/A and -426 T/C in the eotaxin gene (CCL11, 17q 21.3) with the development and clinical aspects of psoriasis as an immune-based dermatological disease and evaluate its relationship to potential comorbidities. Material and Methods: In total, 460 patients with psoriasis were included in the case-control and genotype-phenotype study together with 167 control persons of similar age and sex distributions without a personal and/or family history of chronic disease of the skin. Two eotaxin gene polymorphisms were detected from isolated DNA via standard PCR, restriction analysis methods, and horizontal electrophoresis. Results: No significant case-control differences in the frequency of the CCL11 genotype in both polymorphisms were observed. In polymorphism +67 G/A, a significant increase in the AA genotype in patients with psoriasis guttata compared to plaque psoriasis was found (p = 0.006). A significant association of the A allele in psoriatic patients with a personal history of allergy was found (p = 0.02). The A alle was also significantly associated with a family history of psoriasis (p = 0.00008). In men, a higher risk of a delayed start of psoriasis (later than 40 years) associated with the T allele of -426 T/C polymorphism (p = 0.0007) was found. When double genotypes of both polymorphisms were evaluated, we observed significant differences in double genotype distribution between men with and without a family history of allergy (Pdg = 0.0005) and between those with and without affected siblings (Pdg = 0.03). In women with psoriasis, a higher risk of the TT genotype of -426 T/C polymorphism in patients with a personal history of diabetes (p = 0.001) as well as in patients with both a personal history of cardiovascular disease and diabetes (p = 0.00005) was proved. When double genotypes of both polymorphisms were evaluated, the significance of double genotype difference between those with and without personal history of diabetes was very high (Pdg = 0.0002). Similarly, the significance of the double genotype difference between those with and without personal history of cardiovascular diseases and diabetes was very high (Pdg = 0.000001). Conclusions: CCL11 is considered one of the basic chemokines responsible for the origin and development of immune-based reactions. Based on our results, we suggest that the +67 G/A CCL11 polymorphism should be considered as a gene modulator of psoriasis in specific subgroups of patients.

1st Department of Dermatovenereology St Ann's Faculty Hospital Faculty of Medicine Masaryk University 602 00 Brno Czech Republic

Department of Pathophysiology Faculty of Medicine Masaryk University 625 00 Brno Czech Republic

Psychiatrie Brno Martinkova 253 7 Černá Pole 612 00 Brno Czech Republic

Zobrazit více v PubMed

Guo J., Zhang H., Lin W., Lu L., Su J., Chen X. Signaling pathways and targeted therapies for psoriasis. Signal Transduct. Target. Ther. 2023;8:437. doi: 10.1038/s41392-023-01655-6. Erratum in: Signal Transduct. Target. Ther. 2024, 9, 25. PubMed DOI PMC

Shi Z.R., Mabuchi T., Riutta S.J., Wu X., Peterson F.C., Volkman B.F., Hwang S.T. The Chemokine, CCL20, and Its Receptor, CCR6, in the Pathogenesis and Treatment of Psoriasis and Psoriatic Arthritis. J. Psoriasis Psoriatic Arthritis. 2023;8:107–117. doi: 10.1177/24755303231159106. PubMed DOI PMC

Sieminska I., Pieniawska M., Grzywa T.M. The Immunology of Psoriasis-Current Concepts in Pathogenesis. Clin. Rev. Allergy Immunol. 2024;66:164–191. doi: 10.1007/s12016-024-08991-7. PubMed DOI PMC

Bozó R., Flink L.B., Ambrus B., Ghaffarinia A., Koncz B., Kui R., Gyulai R., Kemény L., Bata-Csörgő Z. The Expression of Cytokines and Chemokines Potentially Distinguishes Mild and Severe Psoriatic Non-Lesional and Resolved Skin from Healthy Skin and Indicates Different Stages of Inflammation. Int. J. Mol. Sci. 2024;25:11292. doi: 10.3390/ijms252011292. PubMed DOI PMC

Zdanowska N., Kasprowicz-Furmańczyk M., Placek W., Owczarczyk-Saczonek A. The Role of Chemokines in Psoriasis—An Overview. Medicina. 2021;57:754. doi: 10.3390/medicina57080754. PubMed DOI PMC

Guttman-Yassky E., Krueger J.G. Atopic dermatitis and psoriasis: Two different immune diseases or one spectrum? Curr. Opin. Immunol. 2017;48:68–73. doi: 10.1016/j.coi.2017.08.008. PubMed DOI

Sun Z., Vattepu R., Zhang S. Chemokines and Innate Lymphoid Cells in Skin Inflammation. Cells. 2021;10:3074. doi: 10.3390/cells10113074. PubMed DOI PMC

Teixeira A.L., Gama C.S., Rocha N.P., Teixeira M.M. Revisiting the Role of Eotaxin-1/CCL11 in Psychiatric Disorders. Front. Psychiatry. 2018;9:241. doi: 10.3389/fpsyt.2018.00241. PubMed DOI PMC

Brunner P.M., Suárez-Fariñas M., He H., Malik K., Wen H.C., Gonzalez J., Chan T.C., Estrada Y., Zheng X., Khattri S., et al. The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins. Sci. Rep. 2017;7:8707. doi: 10.1038/s41598-017-09207-z. PubMed DOI PMC

Gutierrez-Ramos J., Lloyd C., Gonzalo J. Eotaxin: From an eosinophilic chemokine to a major regulator of allergic reactions. Immunol. Today. 1999;20:500–504. doi: 10.1016/S0167-5699(99)01522-4. PubMed DOI

Bui A., Liu J., Hong J., Hadeler E., Mosca M., Brownstone N., Liao W. Identifying Novel Psoriatic Disease Drug Targets Using a Genetics-Based Priority Index Pipeline. J. Psoriasis Psoriatic Arthritis. 2021;6:185–197. doi: 10.1177/24755303211026023. PubMed DOI PMC

Kincl V., Máchal J., Drozdová A., Panovský R., Vašků A. The Relation between eNOS -786 C/T, 4 a/b, MMP-13 rs640198 G/T, Eotaxin 426 C/T, -384 A/G, and 67 G/A Polymorphisms and Long-Term Outcome in Patients with Coronary Artery Disease. Dis. Markers. 2015;2015:232048. doi: 10.1155/2015/232048. PubMed DOI PMC

Darvish Z., Ghanbari S., Afshar S., Tapak L., Amini P. Psoriasis Associated Hub Genes Revealed by Weighted Gene Co-Expression Network Analysis. Cell J. 2023;25:418–426. PubMed PMC

Dand N., Mahil S.K., Capon F., Smith C.H., Simpson M.A., Barker J.N. Psoriasis and Genetics. Acta Derm. Venereol. 2020;100:adv00030. doi: 10.2340/00015555-3384. PubMed DOI PMC

Zou C., Zhang W., Li M., He D., Han Y., Liu M., Lu M. Association between CCL5, CCL11, and CCL17 polymorphisms and atopic dermatitis risk: A systematic review and meta-analysis. Medicine. 2024;103:e36897. doi: 10.1097/MD.0000000000036897. PubMed DOI PMC

Kang W.S., Kim Y.J., Park H.J., Kim S.K., Paik J.W., Kim J.W. Association of CCL11 promoter polymorphisms with schizophrenia in a Korean population. Gene. 2018;656:80–85. doi: 10.1016/j.gene.2018.02.053. PubMed DOI

Tedeschi A., Asero R., Lorini M., Marzano A., Cugno M. Serum eotaxin levels in patients with chronic spontaneous urticaria. Eur. Ann. Allergy Clin. Immunol. 2012;44:188–192. PubMed

Lee J., Jang A., Park S., Kim D., Park C. Gene-Gene Interaction Between CCR3 and Eotaxin Genes: The Relationship with Blood Eosinophilia in Asthma. Allergy Asthma Immunol. Res. 2014;6:55–60. doi: 10.4168/aair.2014.6.1.55. PubMed DOI PMC

Gaspar K., Kukova G., Bunemann E., Buhren B.A., Sonkoly E., Szollosi A.G., Muller A., Savinko T., Lauerma A.I., Alenius H., et al. The chemokine receptor CCR3 participates in tissue remodeling during atopic skin inflammation. J. Dermatol. Sci. 2013;71:12–21. doi: 10.1016/j.jdermsci.2013.04.011. PubMed DOI

Pavel A.B., Del Duca E., Cheng J., Wu J., Ungar B., Estrada Y.D., Jack C., Maari C., Proulx É.S., Ramirez-Valle F., et al. Delayed type hypersensitivity reactions to various allergens may differently model inflammatory skin diseases. Allergy. 2023;78:178–191. doi: 10.1111/all.15538. PubMed DOI